---
title: "XTALPI will receive milestone payments of tens of millions of Hong Kong dollars, with its stock price soaring nearly 50% in the first 14 days of the year"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/272491633.md"
description: "XTALPI announced that its incubated company ReviR has successfully achieved dual filing and approval for the RTX-117 drug pipeline in both China and the United States, receiving milestone payments of tens of millions of Hong Kong dollars. ReviR will continue the clinical development of RTX-117, and XTALPI has the right to participate in sales revenue sharing. Since the beginning of 2026, XTALPI's stock price has risen nearly 47%, currently priced at HKD 13.98, with a total market capitalization of HKD 60.161 billion"
datetime: "2026-01-14T03:17:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272491633.md)
  - [en](https://longbridge.com/en/news/272491633.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272491633.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/272491633.md) | [繁體中文](https://longbridge.com/zh-HK/news/272491633.md)


# XTALPI will receive milestone payments of tens of millions of Hong Kong dollars, with its stock price soaring nearly 50% in the first 14 days of the year

On January 14th, XTALPI announced that its incubated company ReviR (hereinafter referred to as "ReviR") has recently achieved a milestone of successfully obtaining "dual reporting and dual approval" (IND approval) for its innovative drug pipeline RTX-117 in both China and the United States. With the successful progress of multiple collaborations, XTALPI will receive milestone payments totaling tens of millions of Hong Kong dollars from ReviR. ReviR will continue to complete the subsequent clinical development of RTX-117, and XTALPI has the right to participate in the sales revenue sharing and subsequent licensing revenue sharing of this pipeline.

According to Times Finance, in less than half a month since the beginning of 2026, XTALPI's stock price has increased by more than 47%. As of the time of publication, the company's stock price is HKD 13.98 per share, up 3.94%, with a total market value of HKD 60.161 billion. (Times Finance, Du Sumin)

### 相关股票

- [XTALPI (02228.HK)](https://longbridge.com/zh-CN/quote/02228.HK.md)

## 相关资讯与研究

- [Huatai Securities Remains a Buy on Greentown China Holdings (GTWCF)](https://longbridge.com/zh-CN/news/281608307.md)
- [Agile Group Posts RMB1.82 Billion in First-Quarter 2026 Presales](https://longbridge.com/zh-CN/news/281504091.md)
- [CATL's controlling shareholder to donate some A-shares](https://longbridge.com/zh-CN/news/281197776.md)
- [Saudi IPOs slow as listings drop to eight-year low](https://longbridge.com/zh-CN/news/281269797.md)
- [Greentown China Holdings (SEHK:3900) Thin 0.05% Net Margin Reinforces Bearish Narratives](https://longbridge.com/zh-CN/news/281382795.md)